Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacol Biochem Behav ; 124: 269-77, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24951841

ABSTRACT

Estrous cycle-related fluctuations in delta-9-tetrahydrocannabinol (THC)-induced antinociception have been observed in the rat. The aim of this study was to determine which major ovarian hormone modulates the antinociceptive effects of i.c.v. THC, and whether hormone modulation of THC's behavioral effects could be due to changes in brain cannabinoid receptors (CBr). Vehicle (oil) or hormones (estradiol or progesterone, or both) were administered to female rats on days 3 and 7 post-ovariectomy. On the morning or afternoon of day 8 or day 9, vehicle or THC (100 µg) was administered i.c.v. Paw pressure, tail withdrawal, locomotor activity and catalepsy tests were conducted over a 3-h period. Estradiol (with and without progesterone) enhanced THC-induced paw pressure antinociception only. Ovarian hormones time-dependently modulated CBr in brain structures that mediate antinociception and locomotor activity, but the changes observed in CBr did not parallel changes in behavior. However, the time course of CBr changes must be further elucidated to determine the functional relationship between receptor changes and antinociceptive sensitivity to THC.


Subject(s)
Analgesics/pharmacology , Dronabinol/pharmacology , Gonadal Steroid Hormones/pharmacology , Ovary/metabolism , Receptors, Cannabinoid/metabolism , Animals , Catalepsy/chemically induced , Dronabinol/metabolism , Female , Gonadal Steroid Hormones/administration & dosage , Gonadal Steroid Hormones/blood , Locomotion/drug effects , Organ Size/drug effects , Protein Binding , Radioimmunoassay , Rats , Rats, Sprague-Dawley , Uterus/drug effects , Vagina/cytology , Vagina/drug effects
2.
Br J Pharmacol ; 160(3): 530-43, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20590563

ABSTRACT

Endogenous cannabinoid signalling is widespread throughout the body, and considerable evidence supports its modulatory role in many fundamental physiological processes. The daily and seasonal cycles of the relationship of the earth and sun profoundly affect the terrestrial environment. Terrestrial species have adapted to these cycles in many ways, most well studied are circadian rhythms and hibernation. The purpose of this review was to examine literature support for three hypotheses: (i) endocannabinoid signalling exhibits brain region-specific circadian rhythms; (ii) endocannabinoid signalling modulates the rhythm of circadian processes in mammals; and (iii) changes in endocannabinoid signalling contribute to the state of hibernation. The results of two novel studies are presented. First, we report the results of a study of healthy humans demonstrating that plasma concentrations of the endocannabinoid, N-arachidonylethanolamine (anandamide), exhibit a circadian rhythm. Concentrations of anandamide are threefold higher at wakening than immediately before sleep, a relationship that is dysregulated by sleep deprivation. Second, we investigated differences in endocannabinoids and congeners in plasma from Marmota monax obtained in the summer and during the torpor state of hibernation. We report that 2-arachidonoylglycerol is below detection in M. monax plasma and that concentrations of anandamide are not different. However, plasma concentrations of the anorexigenic lipid oleoylethanolamide were significantly lower in hibernation, while the concentrations of palmitoylethanolamide and 2-oleoylglycerol were significantly greater in hibernation. We conclude that available data support a bidirectional relationship between endocannabinoid signalling and circadian processes, and investigation of the contribution of endocannabinoid signalling to the dramatic physiological changes that occur during hibernation is warranted.


Subject(s)
Cannabinoid Receptor Modulators/physiology , Circadian Rhythm/physiology , Endocannabinoids , Signal Transduction/physiology , Animals , Brain/metabolism , Cannabinoid Receptor Modulators/blood , Cannabinoid Receptor Modulators/metabolism , Hibernation/physiology , Humans , Physiological Phenomena
3.
Life Sci ; 77(21): 2603-10, 2005 Oct 07.
Article in English | MEDLINE | ID: mdl-15978627

ABSTRACT

The antagonism of some effects of inhalation general anesthetic agents by naloxone suggests that there may be an opioid component to anesthetic action. There is evidence that this opioid action component is due to neuronal release of endogenous opioid peptides. The strongest evidence is provided by studies that monitor changes in the concentration of opioid peptides in the perfused brain following inhalation of the anesthetic. Indirect or circumstantial evidence also comes from studies of anesthetic effects on regional brain levels of opioid peptides, antagonism of selected anesthetic effects by antisera to opioid peptides and anesthetic-induced changes radioligand binding to opioid receptors. It is likely that some inhalation general anesthetics (e.g., nitrous oxide) can induce neuronal release of opioid peptides and that this may contribute to certain components of general anesthesia (e.g., analgesia). More definitive studies utilizing in vivo microdialysis or autoradiography in selected areas of the brain during induction and successive states of general anesthesia have yet to be conducted.


Subject(s)
Anesthetics, Inhalation/pharmacology , Endorphins/metabolism , Neurons/metabolism , Anesthesia, General , Animals , Brain Chemistry/drug effects , Endorphins/blood , Humans , Neurons/drug effects , Radioligand Assay , Receptors, Opioid/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...